Similar articles

• The Avandia debate: an unhappy conclusion.

  Bloomgarden Z, Handelsman Y. Bloomgarden Z, et al. J Diabetes. 2010 Dec;2(4):221-2. doi: 10.1111/j.1753-0407.2010.00096.x. J Diabetes. 2010. PMID: 20923505 No abstract available.
• Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.

  Misbin RI. Misbin RI. Diabetes Care. 2007 Dec;30(12):3141-4. doi: 10.2337/dc07-1908. Diabetes Care. 2007. PMID: 18042753 Review. No abstract available.
• Avandia in perspective.

  Comarow A. Comarow A. US News World Rep. 2007 Oct 1;143(11):71. US News World Rep. 2007. PMID: 17957906 No abstract available.
• Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.

  [No authors listed] [No authors listed] Harv Heart Lett. 2007 Aug;17(12):1-2. Harv Heart Lett. 2007. PMID: 17717888 No abstract available.
• Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.

  Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Kaul S, et al. Circulation. 2010 Apr 27;121(16):1868-77. doi: 10.1161/CIR.0b013e3181d34114. Epub 2010 Feb 23. Circulation. 2010. PMID: 20179252 No abstract available.